Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Hair Testing to Detect Long-term Methamphetamine Use in People Living with and without HIV.

Journal of acquired immune deficiency syndromes (1999)·2026

Same author

Trends in HIV Viral Suppression in the POP-UP Low-Barrier Care Program for People With HIV Experiencing Homelessness or Unstable Housing.

Open forum infectious diseases·2026

Same author

Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital.

Drug and alcohol review·2026

Same author

Corrigendum to: Factors associated with delayed diagnosis of hepatitis B in southeastern Sydney.

Public health research & practice·2026

Same author

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.

JAMA psychiatry·2026

Search research articles

Related Experiment Video

Updated: Jun 21, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Long-acting HIV Treatments: Study Design, Logistics, and Access.

Nicholas A Murdock¹, Nayri E Alajaji¹, Robin Schaefer¹

¹Forum for Collaborative Research, University of California, Berkeley, Washington, DC, USA.

Open Forum Infectious Diseases

|July 10, 2024

Summary

New long-acting HIV treatments show promise, but clinical trials often exclude key populations disproportionately affected by HIV. Improving trial inclusivity is crucial for effective long-acting HIV therapy access.

Keywords:

HIV-1 inclusivity long-acting HIV treatment marginalized populations trial design

More Related Videos

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 21, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

Clinical Trials
HIV/AIDS Research
Public Health

Background:

Long-acting HIV treatments offer a potential paradigm shift in managing the HIV epidemic.
Current Phase 3 clinical trials frequently underrepresent diverse populations disproportionately impacted by HIV.
Marginalized groups, including women, racial minorities, and individuals with substance use disorders, face adherence challenges with daily regimens.

Purpose of the Study:

To address the underrepresentation of key populations in clinical trials for long-acting HIV treatments.
To explore innovative study designs and implementation strategies for inclusive long-acting HIV therapy research.
To inform optimal care approaches, treatment guidelines, and access policies for long-acting HIV medications.

Main Methods:

Summary of discussions from a multistakeholder workshop focused on study designs for long-acting HIV treatments.
Analysis of challenges in clinical trial inclusivity for HIV treatment research.
Exploration of innovative trial designs and programmatic implementation strategies.

Main Results:

Identified significant underrepresentation of key populations in existing HIV treatment trials.
Highlighted the need for targeted approaches to improve inclusivity in long-acting HIV therapy research.
Discussed potential of innovative trial designs to enhance participation of marginalized groups.

Conclusions:

Inclusive clinical trial designs are essential for the equitable development and access of long-acting HIV treatments.
Addressing the specific needs of underrepresented populations can optimize care and inform policy.
Innovative strategies are needed to ensure long-acting HIV therapies benefit all populations affected by the epidemic.